Oncology

The Non-small cell lung cancer therapeutics market is anticipated to improve owing to better diagnostics methodologies and treatment options across the world. This would expand the NSCLC market size enabling the drug manufacturers to penetrate more into the market. Companies across the globe are diligently working toward the development of new therapies for NSCLC treatment. The launch of below mentioned emerging therapies along with others is expected to significantly impact the treatment scenario of Non-Small Cell Lung Cancer in the coming years, 2019–2028. Tislelizumab, an investigational humanized IgG4 anti-PD-1 monoclonal antibody under development by a Chin...